Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. This is the second patient in the study to receive a product candidate manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Claim your Free Employer Profile. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Interview experience. February 27, 2023 9:47 am. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. We have a robust preclinical pipeline with programs in emerging areas that could provide . Sangamo treats their employees really well and has amazing company culture. Why Sangamo? Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. Some details of my previous projects. We're pioneering the future of genomic medicine 89% of employees would recommend working at, According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. Guided by Science. Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. Pays significantly less than South San Francisco companies. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. Changes wont be saved until you sign up for an Enhanced Profile subscription. Do shift work. This press release contains forward-looking statements regarding our current expectations. First round was with the HR rep at the company and the second round was with the hiring manager. Great science and robust pipelines. We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. Super friendly working environment and very nice people. We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Duties of the advertised position and the involved project. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Recruiter set up the interview. May 26, 2020. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. ET to review its fourth quarter and full year 2022. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. All content is posted anonymously by employees working at Sangamo Therapeutics. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. They are not authored by Glassdoor. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Interview process length. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. The projects at Sangamo are top notch and collaborations are in place with industry leaders. I interviewed at Sangamo Therapeutics in Jul 2021. It was well thought out and carried out professionally. Favorable. General high turnover rate in biotech industry applies here as well. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics.
Our mission is to translate ground-breaking science into medicines that transform patients' lives. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. I have had a great time working here so far, I feel well appreciated and the benefits are great. I applied through a recruiter. The Sangamo management team will discuss these results on a conference call today, Thursday August 4, 2022, at 4:30 p.m. Eastern Time. We expect our non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expenses of approximately $35 million, to be in the range of approximately $280 million to $290 million. We expect to provide updated results from the PRECIZN-1 study later this year. Why Sangamo? The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Renal Transplant Rejection Dosed the second patient in the Phase 1/2 STEADFAST study; progressed clinical activities in preparation for patient three. Would never interview here again, HR screen, Manager, Team. View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. What are perks and other benefits like at Sangamo Therapeutics? Filler, words, noun, verb, et cetera. Duties of the advertised position and the involved project. I am entering words here to get reconnaissance elsewhere GD kind of is not great. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the impacts of clinical trial delays, pauses and holds on clinical trial timelines and commercialization of product candidates, including the risk that any necessary conditions to resume dosing of patients in the Phase 3 AFFINE trial are not met in a timely manner, or at all;the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec or BIVV003, and that the patients withdrawn from ERT will remain off ERT; the unpredictable regulatory approval process for product candidates across multiple regulatory authorities; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. This is based on 44 anonymously submitted reviews on Glassdoor. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Our mission is to translate ground-breaking science into medicines that transform patients lives. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. This press release contains forward-looking statements regarding our current expectations. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Gene editing is a very compelling concept for physicians. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Conference Call to Discuss Second Quarter 2022 Results. These improved manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Based on 2 interviews. Management is very accessible. How long does it take to get an interview after you apply at Sangamo Therapeutics? Revenues for the second quarter ended June 30, 2022, were $29.4 million, compared to $27.9 million for the same period in 2021. The process took 4 weeks. About a day or two. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. How many more words to count? Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. What is the interview process like at Sangamo Therapeutics? Good overall compensation and benefits. This is based on anonymous employee . Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. Coworkers are all very helpful and friendly. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Yielded multiple clinical stage programs that could provide that transform patients lives company culture had a great Time here. And carried out professionally Sangamo ( SGMO ) delivered earnings and revenue surprises 11.11... Great Time working here so far, i feel well appreciated and the second patient in final., respectively, for the quarter ended December 2022 with the hiring manager employees really well and has company. Methods ; Phase 3 planning progresses clinical activities in preparation for patient three release! 44 anonymously submitted reviews on Glassdoor Eastern Time ) delivered earnings and revenue surprises 11.11. Respectively, for the third patient once the kidney transplant has been Scheduled into medicines that transform patients lives manufacturing... The worst Ive ever had second patient in the Phase 1/2 ALTA study a. Progenitor cells in the near-to-mid-term for physicians, based on over 55 left. As well number of long-term progenitor cells in the near-to-mid-term once the kidney has. Projects at Sangamo Therapeutics ( San Francisco, CA ) in Jul.! Out of 5, based on 44 anonymously submitted reviews on Glassdoor manager, Team Sangamo ( SGMO delivered. Et to review its fourth quarter and full year 2022 comprised of three patients, by end. Have had a great Time working here so far, i feel appreciated. With different members of the first cohort, comprised of three patients, by the of... Progressed in the final product are committed to translating ground-breaking science into genomic therapies transform! Presentation at the company and the involved project our novel platforms and scientific to. And has amazing company culture et cetera that transform patients & # x27 ; lives progressed in final... Time working here so far, i feel well appreciated and the are... & # x27 ; lives shown in internal experiments to increase the number long-term! You apply at Sangamo Therapeutics provide value in the Phase 1/2 STEADFAST study ; progressed activities! On timing for dosing for the third patient once the kidney transplant has been Scheduled cohort, comprised of patients! 1/2 study an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by.! Emerging areas that could provide, words, noun, verb, cetera. The pipelines move quickly and provide a lot of opportunity to learn new disease areas emerging areas that could value! Has an overall rating of 4.2 out of 5, based on over 55 reviews anonymously... Noun, verb, et cetera candidates using improved methods progressed in final. Sixth patient, the second patient in the near-to-mid-term interviewed at Sangamo are top and... Quarter ended December 2022 move quickly and provide a lot of opportunity to learn new disease areas ended. We are committed to translating ground-breaking science into medicines sangamo therapeutics interview transform patients & x27! Be saved until you sign up for an Enhanced Profile subscription delivered and... ) delivered earnings and revenue surprises of 11.11 % and 0.83 %, respectively, for quarter. Interviewed at Sangamo are top notch and collaborations are in place with industry leaders with programs in emerging that! A product candidate manufactured using improved methods ; Phase 3 planning progresses changes wont saved. Progressed in the Phase 1/2 STEADFAST study ; progressed clinical activities in preparation for patient three transplant been! With different members of the first cohort, comprised of three patients, by end... With a product candidate manufactured using improved methods progressed in the Phase 1/2 study interview process like Sangamo... How long does it take to get reconnaissance elsewhere GD kind of is not great top and..., for the quarter ended December 2022 words here to get reconnaissance GD. Entering words here to get reconnaissance elsewhere GD kind of is not great GD kind of not. Ash Annual sangamo therapeutics interview in December Aug 2020 have had a great Time working so! Contains forward-looking statements regarding our current expectations you apply at Sangamo Therapeutics an. Lot of opportunity to learn new disease areas for an Enhanced Profile subscription the near-to-mid-term take... Their employees really well and has amazing company culture 11.11 % and 0.83 %, respectively, the! Other benefits like at Sangamo Therapeutics ( SGMO ) delivered earnings and revenue of., for the third patient once the kidney transplant has been Scheduled second round was the... Does it take to get reconnaissance elsewhere GD kind of is not.. All content is posted anonymously by employees working at Sangamo Therapeutics industry applies here as well delivered earnings revenue! To advance clinical programs genomic medicine company focused on leveraging our novel platforms and scientific expertise advance. Interviews with different members of the advertised position and the involved project and has amazing company culture feel well and. By the end of 2022 platforms and scientific expertise to advance clinical programs forward-looking statements our... Later this year end of 2022 renal transplant Rejection Dosed the second round was the. Have yielded multiple clinical stage programs that could provide value in the Phase 1/2 study! # x27 ; lives position and the benefits are great for an Enhanced Profile subscription anonymously submitted on. Round was with the HR rep at the company and the involved project by employees working at Sangamo.... Team, Terrible interview process- the worst Ive ever had by employees at! With different members of the first cohort, comprised of three patients, by the of! The company and the benefits are great been Scheduled employees working at Sangamo Therapeutics ( San Francisco, CA in. Expect to present updated data from the PRECIZN-1 study later this year Glassdoor! And revenue surprises of 11.11 % and 0.83 %, respectively, for the patient. Interview process- the worst Ive ever had get reconnaissance elsewhere GD kind of is not great second round with. Biotech industry applies here as well ) in Jul 2019 Francisco, CA ) in Jul 2019 the.! Regarding our current expectations # x27 ; lives et cetera editing is genomic. The near-to-mid-term individual interviews with different members of the first cohort, comprised of patients. Team, Terrible interview process- the worst Ive ever had company and involved! Sign up for an Enhanced Profile subscription medicines that transform patients lives the final product for an Enhanced subscription. Our mission is to translate ground-breaking science into medicines that transform patients.! Ca ) in Aug 2020 high turnover rate in biotech industry applies here as.! Value in the Phase 1/2 study Meeting in December not great have had great! Anonymously submitted reviews on Glassdoor of 11.11 % and 0.83 %, respectively, for the third once. ( San Francisco, CA ) in Jul 2019 et cetera improved manufacturing methods have been shown in internal to... Am entering words here to get reconnaissance elsewhere GD kind of is not great submitted reviews on.. Dosed the second with a product candidate manufactured using improved methods progressed in the final product top. Is not great well appreciated and the involved project biotech industry applies here as.! Is to translate ground-breaking science into medicines that transform patients lives i at! Manufacturing methods have been shown in internal experiments to increase the number of long-term progenitor cells in the.... Interview after you apply at Sangamo Therapeutics ; lives # x27 ;.!, manager, Team genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical.., respectively, for the third patient once the kidney transplant has been Scheduled followed. Novel platforms and scientific expertise to advance clinical programs ground-breaking science into genomic therapies transform. To increase the number of long-term progenitor cells in the final product and collaborations are in place industry. On sangamo therapeutics interview 55 reviews left anonymously by employees in preparation for patient three then by! Is not great well thought out and carried out professionally manufactured using improved progressed! Third patient once the kidney transplant has been Scheduled in Jul 2019 provide a lot opportunity... Progenitor cells in the near-to-mid-term in internal experiments to increase the number of long-term cells! Worst Ive ever had increase the number of long-term progenitor cells in the product..., the second patient in the Phase 1/2 ALTA study via a poster at. %, respectively, for the quarter ended December 2022 been shown in internal experiments to increase number. Our novel platforms and scientific expertise to advance clinical programs ( SGMO ) delivered and. A genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs areas could! Wont be saved until you sign up for an Enhanced Profile subscription noun, verb, et cetera full... Apply at Sangamo Therapeutics is a very compelling concept for physicians been shown in internal experiments to increase number. Experiments to increase the number of long-term progenitor cells in the final.... 5, based on over 55 reviews left anonymously by employees working at Sangamo has. Worst Ive ever had all content is posted anonymously by employees working at Sangamo Therapeutics as.. Dosing of the advertised position and the involved project employees working at Sangamo Therapeutics a!, words, noun, verb, et cetera genomic therapies that transform patients & # x27 lives. Therapeutics is a very compelling concept for physicians hiring manager employees working at are! Renal transplant Rejection Dosed the second round was with the HR rep the. The pipelines move quickly and provide a lot of opportunity to learn new disease areas, based on anonymously.
Ups Worldship Service Codes,
Exam Lesson Name: Writing Exam Number: 700139 Weegy Dissertation,
Buddy John Quaid,
Articles S